Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients

Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) predominantly occurs in adults ≥60 years old; 10–20% of cases are pediatric or adolescent/young adult (AYA) patients. Tagraxofusp (TAG, Elzonris®) is the only approved treatment for BPDCN; in the United States it is approved for patients...

Full description

Bibliographic Details
Main Authors: Naveen Pemmaraju, Branko Cuglievan, Joseph Lasky, Albert Kheradpour, Nobuko Hijiya, Anthony S. Stein, Soheil Meshinchi, Craig A. Mullen, Emanuele Angelucci, Luciana Vinti, Tariq I. Mughal, Anna B. Pawlowska
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:eJHaem
Subjects:
AYA BPDCN
CD123
pediatric BPDCN
plasmacytoid dendritic cells
tagraxofusp
Online Access:https://doi.org/10.1002/jha2.856

Internet

https://doi.org/10.1002/jha2.856

Similar Items